1. Scrip
  2. >>COVID-19

Novavax’s COVID-19 Shot Finally Authorized In US, But Could Miss Out Again On Bivalent Booster

Still Hoping To Hit $4bn Revenues Despite Slow Start

 
• By Andrew McConaghie

A protein-based vaccine for COVID-19 reaches the US at last, but Novavax looks set miss out once again as the fall deadline for BA.4/5 variant-targeting vaccines approaches.

Novavax flag
Novavax will not catch up with Pfizer or Moderna, but the vaccine's EUA is nevertheless an inflection point for the company. • Source: Shutterstock

Novavax’s much-delayed COVID-19 vaccine NVX-CoV2373 has finally gained an emergency use authorization in the US, making it the first protein-based vaccine to be cleared for the disease alongside the widely used mRNA-based shots, BioNTech/Pfizer’s Comirnaty and Moderna’s SpikeVax.

The company once hoped to be a close rival to these products with its nanoparticle technology, but that goal looks...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

2030’s Top Therapies: Incretin Agonists Loom Large

 
• By Edwin Elmhirst

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.